Attitudes and Unmet Needs Among Type 2 Diabetes Patients

Completed

• Conditions: Type 2 Diabetes
• Interventions: Other: No treatment given

• Registration Number: NCT05737810
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

The main purpose of this study is to explore experiences and understand the unmet needs of people with Type 2 Diabetes (T2D) among those who are being managed with basal insulin and those who are insulin naïve in order to understand perspectives for a once weekly insulin option; including any potential barriers to being managed with insulin therapy overall. Study participants will be recruited to complete a 15-minute self-administered online survey.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-02-10
• Study First Submitted QC: 2023-02-10
• Study First Posted: 2023-02-21
• Study Start: 2023-03-27
• Primary Completion: 2023-04-17
• Study Completion: 2023-04-17
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-12
• Last Update Posted: 2023-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 700

Inclusion Criteria

1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
2. Male or female, age above or equal between 18 to 65 years at the time of signing informed consent.
3. Diagnosed with T2D and currently treating T2D with at least one medication
4. Insulin user that is not using insulin pump
5. Lives in a target country

Exclusion Criteria

1. Previous participation in this study. Participation is defined as having given informed consent in this study
2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
3. Does not meet inclusion criteria requirements

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
People with Type 2 Diabetes	No treatment given	Participants are recruited via email through online panel companies

Primary Outcome Measures

Name	Time	Method
Injection perceptions	At the time of survey response (Day1)	Likert scale for measurement of agreement from 1 "strongly disagree" to 7 "strongly agree"
Current medication burden	At the time of survey response (Day1)	Numerical; Multiple select from defined list
Attitudes regarding T2D treatment	At the time of survey response (Day1)	Likert scales for measurement of satisfaction from 1 "extremely unsatisfied" to 7 "extremely satisfied" and agreement from 1 "strongly disagree" to 7 "strongly agree"
Attitudes regarding T2D overall	At the time of survey response (Day1)	Likert scale for measurement of agreement from 1 "strongly disagree" to 7 "strongly agree"
Attitudes regarding insulin icodec	At the time of survey response (Day1)	Likert scales for measurement of likelihood from 0 "not at all likely" to 10" extremely likely" and agreement from 1 "strongly disagree" to 7 "strongly agree; Rank top 3 from defined list

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇬🇧 London, United Kingdom